Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16

Article  PubMed  PubMed Central  Google Scholar 

Evans DG (2009) Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 11:599–610

Article  PubMed  Google Scholar 

Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M (2009) Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28:854–865

Article  CAS  PubMed  Google Scholar 

Martuza RL, Eldridge R (1988) Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 318:684–688

Article  CAS  PubMed  Google Scholar 

Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Wolkenstein P, Evans DG (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967–1977

Article  CAS  PubMed  Google Scholar 

Huang CW, Tu HT, Chuang CY, Chang CS, Chou HH, Lee MT, Huang CF (2018) Gamma Knife radiosurgery for large vestibular schwannomas greater than 3 cm in diameter. J Neurosurg 128:1380–1387

Article  PubMed  Google Scholar 

Yao L, Alahmari M, Temel Y, Hovinga K (2020) Therapy of sporadic and NF2-related vestibular schwannoma. Cancers (Basel) 12:835

Article  CAS  PubMed  Google Scholar 

Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19(1):5–12

Article  CAS  PubMed  Google Scholar 

Fujiwara RJT, Shi JJ, Tan D, Sakano H, Kutz JW (2025) Increased costs and complication rates in vestibular schwannoma resections for neurofibromatosis type 2. Otol Neurotol. https://doi.org/10.1097/MAO.0000000000004442

Article  PubMed  Google Scholar 

McClelland S 3rd, Gerbi BJ, Cho KH, Hall WA (2007) The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy. J Robot Surg 1:227–230

Article  PubMed  PubMed Central  Google Scholar 

Evans DG, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Lavin T, Paterson C, Whitfield G, McCabe MG, Axon PR, Halliday J, Mackeith S, Parry A; English Specialist NF2 Research Group; Harkness EF, Buttimore J, King AT (2023) Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression. Neurooncol Adv 5:vdad025.

Seferis C, Torrens M, Paraskevopoulou C, Psichidis G (2014) Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg 121(Suppl):160–166

Article  PubMed  Google Scholar 

Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA (2019) Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol 37:3446–3454

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mautner VF, Nguyen R, Knecht R, Bokemeyer C (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21:2294–2295

Article  PubMed  Google Scholar 

Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK (2017) Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J Neurooncol 131:117–124

Article  CAS  PubMed  Google Scholar 

Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT (2023) Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol Adv 5:vdad123.

Renzi S, Michaeli O, Salvador H, Alderete D, Ponce NF, Zapotocky M, Hansford JR, Malalasekera VS, Toledano H, Maguire B, Bouffet E, Ramaswamy V, Baroni LV (2020) Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer 67:e28228

Article  PubMed  Google Scholar 

Gugel I, Zipfel J, Hartjen P, Kluwe L, Tatagiba M, Mautner VF, Schuhmann MU (2020) Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. Childs Nerv Syst 36(10):2471–2480

Article  PubMed  PubMed Central  Google Scholar 

Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M (2019) A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 10(1):5758.

Tamura R, Yamanobe Y, Fujioka M, Morimoto Y, Fukumura M, Nakaya M, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ozawa H, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M (2024) Phase I/II study of a vascular endothelial growth factor receptor vaccine in patients with NF2-related schwannomatosis. J Clin Oncol 42(21):2578–2587

Article  CAS  PubMed  Google Scholar 

Henderson ML, Zieba JK, Li X, Campbell DB, Williams MR, Vogt DL, Bupp CP, Edgerly YM, Rajasekaran S, Hartog NL, Prokop JW, Krueger JM (2024) Gene therapy for genetic syndromes: understanding the current state to guide future care. BioTech (Basel) 13:1

Article  CAS  PubMed  Google Scholar 

Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, Khurana I, Banothu AK, Weiskirchen R, Bharani KK (2022) Gene therapy: comprehensive overview and therapeutic applications. Life Sci 294:120375

Article  CAS  PubMed  Google Scholar 

Volodina O, Smirnikhina S (2024) The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol Biotechnol, 16.

Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, Kim Y, Korf B, Leier A, McManus ML, Sarnoff H, Vitte J, Walker JA, Plotkin SR, Wallis D (2024) Gene-targeted therapy for neurofibromatosis and schwannomatosis: the path to clinical trials. Clin Trials 21(1):51–66

Article  PubMed  Google Scholar 

O’Donohue AK, Ginn SL, Burgio G, Berman Y, Dabscheck G, Schindeler A (2025) The evolving landscape of NF gene therapy: hurdles and opportunities. Mol Ther Nucleic Acids 36:1–11

Article  Google Scholar 

Zhang ZY, Wu YY, Cai XY, Fang WL, Xiao FL (2021) Molecular diagnosis of neurofibromatosis by multigene panel testing. Front Genet 12:603195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teranishi Y, Miyawaki S, Hongo H, Dofuku S, Okano A, Takayanagi S, Ota T, Yoshimura J, Qu W, Mitsui J, Nakatomi H, Morishita S, Tsuji S, Saito N (2021) Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J Med Genet 58:701–711

Article  CAS  PubMed  Google Scholar 

Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI (2010) The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell 19:727–739

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pe’cina-Šlaus N. (2013) Merlin, the NF2 gene product. Pathol Oncol Res 19:365–373

Article  Google Scholar 

Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103–119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mota M, Shevde LA (2020) Merlin regulates signaling events at the nexus of development and cancer. Cell Commun Signal 18(1):63

Article  PubMed  PubMed Central  Google Scholar 

Vlashi R, Sun F, Zheng C, Zhang X, Liu J, Chen G (2024) The molecular biology of NF2/Merlin on tumorigenesis and development. FASEB J 38(13):e23809

Article